Payment overview · 2025
General Payments
$219.04
11 reported records · 8 companies
Healthcare provider profile · identity verified
Bhavna Gowda, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · HARTSELLE, AL · NPI 1750557518
Verified facts
What the public records show
CMS Open Payments records show Bhavna Gowda, M.D. received $219.04 in general payments during 2025 across 11 reported records.
Exact Sciences Corporation accounted for 24.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 175 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $53.82 | 24.6% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $43.74 | 20.0% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $25.16 | 11.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $24.51 | 11.2% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $21.07 | 9.6% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $18.55 | 8.5% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.61 | 7.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.58 | 7.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $219.04 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $53.82 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $43.74 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $43.74 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $25.16 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $24.51 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $24.51 | 1 | 2025 |
Source payment records
|
|||||
| Ambulatory Monitoring & Diagnostics Undivided Normalized: ambulatory monitoring diagnostics undivided |
Device | Philips North America LLC | $21.07 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $18.55 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $16.61 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.61 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.58 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 175 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
175 | 30 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 392 | 134 |
| Omeprazole | Omeprazole | 364 | 115 |
| Levothyroxine Sodium | Levothyroxine Sodium | 350 | 100 |
| Lisinopril | Lisinopril | 288 | 97 |
| Metoprolol Succinate | Metoprolol Succinate | 254 | 82 |
| Metformin Hcl | Metformin Hcl | 233 | 80 |
| Amlodipine Besylate | Amlodipine Besylate | 225 | 72 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 223 | 42 |
| Montelukast Sodium | Montelukast Sodium | 215 | 77 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 194 | 51 |
| Ozempic | Semaglutide | 175 | 30 |
| Gabapentin | Gabapentin | 170 | 57 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 170 | 53 |
| Glipizide Er | Glipizide | 169 | 59 |
| Losartan Potassium | Losartan Potassium | 169 | 54 |
| Meloxicam | Meloxicam | 157 | 73 |
| Simvastatin | Simvastatin | 157 | 50 |
| Pantoprazole Sodium | Pantoprazole Sodium | 145 | 41 |
| Furosemide | Furosemide | 142 | 57 |
| Pravastatin Sodium | Pravastatin Sodium | 137 | 40 |
| Hydrochlorothiazide | Hydrochlorothiazide | 132 | 42 |
| Potassium Chloride | Potassium Chloride | 132 | 46 |
| Trazodone Hcl | Trazodone Hcl | 132 | 40 |
| Escitalopram Oxalate | Escitalopram Oxalate | 130 | 41 |
| Alprazolam | Alprazolam | 119 | 25 |
| Atenolol | Atenolol | 119 | 31 |
| Sertraline Hcl | Sertraline Hcl | 119 | 40 |
| Januvia | Sitagliptin Phosphate | 117 | 24 |
| Pioglitazone Hcl | Pioglitazone Hcl | 116 | 35 |
| Allopurinol | Allopurinol | 113 | 31 |
| Buspirone Hcl | Buspirone Hcl | 112 | 27 |
| Carvedilol | Carvedilol | 110 | 33 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 109 | 93 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 106 | 34 |
| Metformin Hcl Er | Metformin Hcl | 98 | 30 |
| Zolpidem Tartrate | Zolpidem Tartrate | 97 | 34 |
| Famotidine | Famotidine | 92 | 32 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 89 | 23 |
| Mounjaro | Tirzepatide | 85 | 16 |
| Memantine Hcl | Memantine Hcl | 84 | 29 |
| Jardiance | Empagliflozin | 81 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 78 | 25 |
| Tramadol Hcl | Tramadol Hcl | 76 | 21 |
| Pregabalin | Pregabalin | 75 | 15 |
| Alendronate Sodium | Alendronate Sodium | 73 | 19 |
| Cephalexin | Cephalexin | 73 | 55 |
| Clonazepam | Clonazepam | 72 | 14 |
| Eliquis | Apixaban | 71 | 18 |
| Spironolactone | Spironolactone | 70 | 23 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 69 | 24 |
| Donepezil Hcl | Donepezil Hcl | 65 | 27 |
| Methylprednisolone | Methylprednisolone | 65 | 55 |
| Fluoxetine Hcl | Fluoxetine Hcl | 57 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 53 | 18 |
| Levofloxacin | Levofloxacin | 53 | 44 |
| Citalopram Hbr | Citalopram Hydrobromide | 52 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 52 | 27 |
| Finasteride | Finasteride | 50 | 12 |
| Celecoxib | Celecoxib | 49 | 19 |
| Fenofibrate | Fenofibrate | 49 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 48 | 18 |
| Ondansetron Odt | Ondansetron | 48 | 18 |
| Repaglinide | Repaglinide | 48 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 48 | 15 |
| Fluconazole | Fluconazole | 46 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 45 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 45 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 40 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 39 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 39 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 37 | suppressed |
| Temazepam | Temazepam | 37 | suppressed |
| Lorazepam | Lorazepam | 35 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 35 | 30 |
| Ipratropium Bromide | Ipratropium Bromide | 33 | suppressed |
| Cefdinir | Cefdinir | 32 | 27 |
| Azithromycin | Azithromycin | 31 | 28 |
| Glimepiride | Glimepiride | 31 | suppressed |
| Trulicity | Dulaglutide | 31 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 31 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | 11 |
| Nystatin | Nystatin | 30 | 17 |
| Meclizine Hcl | Meclizine Hcl | 29 | 17 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 29 | 27 |
| Dicyclomine Hcl | Dicyclomine Hcl | 28 | 13 |
| Prednisone | Prednisone | 28 | 14 |
| Bupropion Hcl Sr | Bupropion Hcl | 27 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 27 | suppressed |
| Eszopiclone | Eszopiclone | 27 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 26 | 20 |
| Naproxen | Naproxen | 26 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 25 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 23 | suppressed |
| Estradiol | Estradiol | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Lactulose | Lactulose | 21 | 13 |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Ezetimibe | Ezetimibe | 19 | suppressed |
| Methocarbamol | Methocarbamol | 19 | 12 |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 18 | suppressed |
| Mupirocin | Mupirocin | 17 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Indomethacin | Indomethacin | 15 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Zafirlukast | Zafirlukast | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Dotti | Estradiol | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $219.04 · 11 records | Exact Sciences Corporation | AIRSUPRA, AREXVY, Ambulatory Monitoring & Diagnostics Undivided, CAPLYTA, Ozempic, QULIPTA, REXULTI, Rybelsus, SHINGRIX, The Cologuard Plus Collection Kit, UBRELVY | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error